Form 4 for TCRX TScan Therapeutics, Inc.
Accepted 2022-05-20 00:00:00 ET · period of report 2022-05-18 · accession 0000899243-22-019018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2022-05-20 | 2022-05-18 | TCRX | SOUTHWELL DAVID P | CEO, Dir | P - Purchase | $3.59 | +25.0K | 171.6K | +17% | +$89.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Voting Common Stock | 2022-05-18 | P | A | 15,000 | $3.62 | 161,569 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $3.379 to $3.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote. |
| 2 | Common | Voting Common Stock | 2022-05-18 | P | A | 10,000 | $3.55 | 171,569 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $3.45 to $3.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote. |